Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cullinan Therapeutics Inc
(NQ:
CGEM
)
18.88
-2.92 (-13.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cullinan Therapeutics Inc
< Previous
1
2
Next >
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
February 02, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
January 24, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
November 02, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
November 01, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
October 25, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.